...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy, Asthma & Clinical Immunology >Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care
【24h】

Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care

机译：英国二级保健中接受奥马珠单抗或环孢素治疗的患者的慢性自发性荨麻疹结局及不良反应的回顾性病例记录回顾

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H 1 -antihistamines. Ciclosporin is an established but unlicensed 3rd line option for CSU. Two parallel retrospective observational studies were conducted to describe outcomes of treatment and adverse events with omalizumab or ciclosporin for CSU treatment. Methods Data from UK specialist centres prescribing omalizumab (five centres) or ciclosporin (three centres) in CSU patients were collected from hospital records by clinical staff and pooled for analysis. Results Forty-six patients prescribed omalizumab and 72 patients prescribed ciclosporin were included. Twenty-two (48%) omalizumab-treated patients had paired Urticaria Activity Scores (UAS7), showing a 25.4 point improvement during treatment (P? Conclusions Validated patient-reported measures of disease severity and quality of life should be used routinely in CSU management. Based on clinician comments and DLQI scores, symptoms and quality of life showed a greater improvement in the omalizumab-treated cohort than in the ciclosporin-treated cohort.
机译：背景Omalizumab在英国被批准作为对H 1 -抗组胺药反应不足的患者的慢性自发性荨麻疹（CSU）的附加治疗药物。环孢素是CSU已建立但未经许可的三线选择。进行了两项平行的回顾性观察研究，以描述奥马珠单抗或环孢素用于CSU治疗的治疗结果和不良事件。方法从临床工作人员的医院记录中收集来自英国专科中心处方奥马珠单抗（五个中心）或环孢菌素（三个中心）的数据，并汇总以进行分析。结果包括46例使用omalizumab的患者和72例使用环孢素的患者。 22名（48％）奥马珠单抗治疗的患者具有成对的荨麻疹活动评分（UAS7），显示治疗期间改善了25.4分（P？结论）在CSU管理中应常规使用经验证的患者报告的疾病严重程度和生活质量衡量指标根据临床医生的评论和DLQI评分，在接受奥马珠单抗治疗的人群中，其症状和生活质量较在环孢素治疗的人群中有更大的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号